Heterogeneity in nanoparticles influences biodistribution and targeting

Nanomedicine

Volumn 9, Issue 2, 2014, Pages 267-278

  Adjei, Isaac M ^a,b   Peetla, Chiranjeevi ^b   Labhasetwar, Vinod ^a,b,c  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Cancer therapy; Drug delivery systems; Drug targeting; Medical imaging; Nanomedicine; Nanostructures

Indexed keywords

CYANINE DYE; DYE; EMULSIFYING AGENT; NANOCARRIER; POLYGLACTIN; POLYVINYL ALCOHOL; QUANTUM DOT; SDA 5177; SDB 5700; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATOMIC FORCE MICROSCOPY; AUTOFLUORESCENCE; CIRCULATION TIME; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG TARGETING; FLUORESCENCE IMAGING; HYDRODYNAMICS; IN VIVO STUDY; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PLASMA CLEARANCE; PRIORITY JOURNAL; PROSTATE TUMOR; SURFACE CHARGE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ZETA POTENTIAL;

ANIMALS; HETEROGRAFTS; MALE; MICE; NANOPARTICLES; PROSTATIC NEOPLASMS; SPECTROSCOPY, NEAR-INFRARED; TISSUE DISTRIBUTION;

EID: 84896696928     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.13.70     Document Type: Article

References (40)

1. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearan ce and biodistribution of polymeric nanoparticles. Mol. Pharmaceutics 5(4), 505-515 (2008).
2. Avgoustakis K, Beletsi A, Panagi Z et al. Effect of copolymer composition on the physicochemical characte ristics, in vitro stability, and biodistribution of PLGA-mPEG nanoparticles. Int. J. Pharm. 259(1-2), 115-127 (2003).
3. Litzinger DC, Buiting AMJ, Van Rooijen N, Huang L. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim. Biophys. Acta 1190(1), 99-107 (1994).
4. Rao DA, Robinson JR. Effect of size and surface properties of biodegradable PLGA-PMA: PLA:PEG nanoparticles on lymphatic uptake and retention in rats. J. Control. Release 132(3), e45-e47 (2008).
5. Xiao K, Li Y, Luo J et al. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials 32(13), 3435-3446 (2011).
6. Yang Z, Leon J, Martin Met al. Pharmacokinetics and biodistribution of near-infrared fluorescence polymeric nanoparticles. Nanotechnology 20(16), 165101 (2009).
7. Beletsi A, Panagi Z, Avgoustakis K. Biodistribution properties of nanoparticles based on mixtures of PLGA with PLGA-PEG diblock copolymers. Int. J. Pharm. 298(1), 233-241 (2005).
8. Lee CC, Gillies ER, Fox ME et al. A single dose of doxorubicin- functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. Proc. Natl Acad. Sci. USA 103(45), 16649-16654 (2006).
9. Duncan R, Izzo L. Dendrimer biocompatibility and toxicity. Adv. Drug Deliv. Rev. 57(15), 2215-2237 (2005).
10. Li Y-P, Pei Y-Y, Zhang X-Y et al. PEGylated PLGA nanoparticles as protein carriers: Synthesis, preparation and bi odistribution in rats. J. Control. Release 71(2), 203-211 (2001).
11. Gbadamosi JK, Hunter AC, Moghimi SM. PEGylation of microspheres generates a heterogeneous population of particles with differ ential surface characteristics and biological performance. FEBS Lett. 532(3), 338-344 (2002).
12. Prabha S, Zhou W-Z, Panyam J, Labhasetwar V. Size-dependency of nanoparticle-mediated gene tr ansfection: Studies with fractionated nanoparticles. Int. J. Pharm. 244(1-2), 105-115 (2002).
13. Lee H, Lytton-Jean AKR, Chen Y et al. Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo SIRNA delivery. Nat. Nanotechnol. 7(6), 389-393 (2012).
14. Marques JT, Williams BRG. Activation of the mammalian immune system by siRNAs. Nat. Biotechnol. 23(11), 1399-1405 (2005).
15. Karik? K, Bhuyan P, Capodici J, Weissman D. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through Toll-like receptor 3. J. Immunol. 172(11), 6545-6549 (2004).
16. Wang S, Dormidontova EE. Nanoparticle design optimization for enhanced targeting: Monte Carlo simulations. Biomacromolecules 11(7), 1785-1795 (2010).
17. Rao KS, Reddy MK, Horning JL, Labhasetwar V. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials 29(33), 4429-4438 (2008).
18. Pirollo KF, Chang EH. Does a targeting ligand influence nanoparticle tumor localization or uptake Trends Biotechnol. 26(10), 552-558 (2008).
19. Foy SP, Manthe RL, Foy ST, Dimitrijevic S, Krishnamurthy N, Labhasetwar V. Optical imaging and magnetic field targeting of magnetic nanoparticles in tumors. ACS Nano 4(9), 5217-5224 (2010).
20. Sharma B, Ma W, Ad jei I, Panyam J, Dimitrijevic S, Labhasetwar V. Nanoparticle-mediated p53 gene therapy for tumor inhibition. Drug Deliv. Transl. Res. 1(1), 43-52 (2011).
21. Kumar R, Roy I, Ohulchanskky TY et al. In vivo biodistribution and clearance studies using multimodal organically modified silica nanoparticles. ACS Nano 4(2), 699-708 (2010).
22. Kim S, Lim YT, Soltesz EG et al. Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat. Biotechnol. 22(1), 93-97 (2004).
23. Nakayama A, Bianco AC, Zhang C-Y, Lowell BB, Frangioni JV. Quantitatio n of brown adipose tissue perfusion in transgenic mice using near-infrared fluorescence imaging. Mol. Imaging 2(1), 37-49 (2003).
24. Decuzzi P, Godin B, Tanaka T et al. Size and shape effect Sin the biodistribution of intravascularly injected particles. J. Control. Release 141(3), 320-327 (2010).
25. Aggarwal P, Hall JB, Mcleland CB, Dobrovolskaia MA, Mcneil SE. Nanopartic le interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv. Drug. Deliv. Rev. 61(6), 428-437 (2009).
26. Lundqvist M, Stigler J, Cedervall T et al. The evolution of the protein corona around nanoparticles: A test study. ACS Nano 5(9), 7503-7509 (2011).
27. Tenzer S, Docter D, Rosfa Set al. Nanoparticle size is a cri tical physicochemical determinant of the human blood plasma corona: A comprehensive quantitative proteomic analysis. ACS Nano 5(9), 7155-7167 (2011).
28. Ehrenberg MS, Friedman AE, Finkelstein JN, Oberd? rster G, McGrath JL. The influence of protein adsorption on nanoparticle association with cultured endothelial cells. Biomaterials 30(4), 603-610 (2009).
29. Gref R, L?ck M, Quellec P et al. ?Stealth?corona-core nanoparticles surface modified by polyethylene glycol (PEG). influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf. B 18(3-4), 301-313 (2000).
30. Adriani G, De Tullio MD, Ferrari Met al. The preferential targeting of the diseased microvasculature by disk-like particles. B iomaterials 33(22), 5504-5513 (2012).
31. Ven ALVD, Wu M, Lowengrub J et al. Integrated intravital microscopy and mathematical modeling to optimize nanotherapeutics delivery to tumors. AIP Adv. 2(1), 11208 (2012).
32. Decuzzi P, Pasqualini R, Arap W, Ferrari M. Intravascular delivery of particulate systems: Does geometry really matter Pharm. Res. 26(1), 235-243 (2009).
33. Sahoo SK, Panyam J, Prabha S, Labhasetwar V. Residual polyvinyl alcohol associated with poly (d,l-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J. Control. Release 82(1), 105-114 (2002).
34. Lynch I, Dawson KA. Protein-nanoparticle interactions. Nano Today 3(1), 40-47 (2008).
35. Singh S, Grossniklaus H, Kang S, Edelhauser H, Ambati B, Kompella U. In travenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. Gene Ther. 16(5), 645-659 (2009).
36. Furumoto K, Ogawara K-I, Yoshida Met al. Biliary excretion of polystyrene microspheres depends on the type of receptor-mediated uptake in rat liver. BBA-General Subjects 1526(2), 221-226 (2001).
37. Chauhan VP, Stylianopoulos T, Martin JD et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat. Nanotechnol. 7(6), 383-388 (2012).
38. Lengyel JS, Milne JLS, Subramaniam S. Electron tomography in nanoparticle imaging and analysis. Nanomedicine (Lond.) 3(1), 125-131 (2008).
39. Wang J, Tian S, Petros RA, Napier ME, Desimone JM. The compl ex role of multivalency in nanoparticles targeting the transferrin receptor for cancer therapies. J. Am. Chem. Soc. 132(32), 11306-11313 (2010).
40. Zhang Y, Tekobo S, Tu Y et al. Permission to enter cell by shape: Nanodisk vs nanosphere. ACS Appl. Mater. Interfaces 4(8), 4099-4105 (2012).